Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody- drug conjugate development

被引：3
|
作者：
Ma, Qi [1 ,2 ]
Durga, Puro [3 ]
Wang, Frederick X. C. [4 ]
Yao, Hang-Ping [5 ]
Wang, Ming-Hai [3 ]
机构：
[1] Ningbo Univ, Affiliated Hosp 1, Translat Res Lab Urol Dis, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Affiliated Hosp 1, Comprehens Genitourinary Canc Ctr, Ningbo, Zhejiang, Peoples R China
[3] Texas Tech Univ Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79430 USA
[4] Houston Methodist Hosp, Dept Med, Houston, TX USA
[5] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Natl Clin Res Ctr Infect Dis, Affiliated Hosp 1,Sch Med, Hangzhou, Zhejiang, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2024年 / 29卷 / 08期
关键词：
antibody -drug conjugates; proprietary technology; technological innovation; IgG antibody engineering; linker chemistry; cytotoxic payload; targeted cancer therapy; biotech-pharmaceutical industry; TRASTUZUMAB DERUXTECAN; ANTITUMOR EFFICACY; CANCER; POTENT; TECHNOLOGY; PAYLOADS; CALICHEAMICIN; THERAPEUTICS; OZOGAMICIN; DISCOVERY;
D O I：
10.1016/j.drudis.2024.104057
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Antibody-drug conjugates (ADCs), from prototypes in the 1980s to first- and second-generation products in the 2000s, and now in their multiformats, have progressed tremendously to meet oncological challenges. Currently, 13 ADCs have been approved for medical practice, with over 200 candidates in clinical trials. Moreover, ADCs have evolved into different formats, including bispecific ADCs, probody-drug conjugates, pH-responsive ADCs, target-degrading ADCs, and immunostimulating ADCs. Technologies from biopharmaceutical industries have a crucial role in the clinical transition of these novel biotherapeutics. In this review, we highlight several features contributing to the prosperity of bioindustrial ADC development. Various proprietary technologies from biopharmaceutical companies are discussed. Such advances in biopharmaceutical industries are the backbone for the success of ADCs in development and clinical application.
引用
收藏
页数：17
相关论文
共 50 条
12345